Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.52 |
| ▸ | RXRB | P28702 | 8/20 | 0.52 |
| ▸ | RXRG | P48443 | 8/20 | 0.52 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.46 |
| ▸ | POLQ | O75417 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428720 | 0.82 | RXRA (0.42) | RXRARXRBRXRGAGBL2PTGDR2 | |
| SCHEMBL29009958 | 0.82 | RXRA (0.42) | RXRARXRBRXRGAGBL2PTGDR2 | |
| SCHEMBL8462688 | 0.78 | RXRA (0.43) | RXRARXRBRXRGAGBL2POLQ | |
| SCHEMBL8464813 | 0.78 | RXRA (0.43) | RXRARXRBRXRGAGBL2POLQ | |
| SCHEMBL5574328 | 0.76 | CES2 (0.53) | RXRARXRBRXRGAGBL2POLQ | |
| SCHEMBL3741058 | 0.76 | POLQ (0.61) | RXRARXRBRXRGPOLQPTGDR2 | |
| SCHEMBL30716953 | 0.76 | POLQ (0.61) | RXRARXRBRXRGPOLQPTGDR2 | |
| SCHEMBL19011781 | 0.75 | CACNA1H (0.36) | POLQCES2 | |
| SCHEMBL6673482 | 0.75 | POLQ (0.41) | RXRARXRBRXRGPOLQ | |
| SCHEMBL20575945 | 0.75 | RXRA (0.57) | RXRARXRBRXRGAGBL2POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1286967-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087838-A1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | RXRA 908/4885RXRB 641/4885RXRG 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.